Drawing for XIGEN

USPTO serial 85510388

XIGEN

Reviewed by CopyMark Law Group

Reg. 4405437Status 710
Filing date
Status date
Registration date
Sep 24, 2013
Examiner
KLINE, MATTHEW
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with XIGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David A. Jackson

DAVID A JACKSON KLAUBER JACKSON LLC25 E SPRING VALLEY AVESTE 160MAYWOOD, NJ 07607 2154

Goods and services

ClassDescriptionStatusFirst use
005Food supplements for medical purposes; pharmaceutical, veterinary and sanitary preparations, namely, anti-inflammatory drugs, inhibitors of cell signalling, anti-cancer drugs, antiinfectives and anti-viral drugs; dietetic substances adapted for medical use, namely, food for babies; adjuvants for medical purposes; proteins for medical purposes; biological preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; pharmaceutical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular and rheumatologic diseases; ferments for pharmaceutical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; hormones for medical purposes; medicinal infusions for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical reagents for medical or veterinary purposes, excluding anti-viral and HIV pharmaceutical preparations and substancesSECTION 8 - CANCELLED—
035Advertising; business management; business administration assistance; providing office functions, providing business analysis and research servicesSECTION 8 - CANCELLED—
042Scientific and technological services and research, namely, pharmaceutical research in particular drug discovery, and design, excluding pharmaceuticals in the HIV and anti-viral therapeutic areas; providing pharmaceutical analysis and research services, excluding pharmaceuticals in the HIV and anti-viral therapeutic areas; design and development of computer hardware and softwareSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 5, 2020C8..CANCELLED SEC. 8 (6-YR)—
Sep 24, 2018REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 24, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 20, 2013TMBNTTAB RELEASE CASE TO TRADEMARKS—
Aug 20, 2013OP.TOPPOSITION TERMINATED NO. 999999—
Aug 20, 2013OP.DOPPOSITION DISMISSED NO. 999999—
Aug 6, 2013MAILPAPER RECEIVED—
Jul 29, 2013MAILPAPER RECEIVED—
Jun 7, 2013OP.IOPPOSITION INSTITUTED NO. 999999—
Jan 3, 2013ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 11, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 11, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 21, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 5, 2012PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 5, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 5, 2012ACECAMENDMENT FROM APPLICANT ENTERED—
Nov 5, 2012CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 5, 2012ALIEASSIGNED TO LIE—
Oct 25, 2012MAILPAPER RECEIVED—
Apr 18, 2012GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2012GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 11, 2012DOCKASSIGNED TO EXAMINER—
Jan 11, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 10, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance